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optimal management of these patients, nor is there reliable information on the cost 
and quality-of-life implications of recurrence. Methods: A patient management 
pathway for one- or two-step abdominal wall reconstructions was developed using 
available literature and surgeon input, and was evaluated using a pilot paper-based 
questionnaire, which was sent to European surgeons with relevant experience. Based 
on responses, a revised version of the questionnaire was created in anonymised iPad 
format for use at surgical conferences. Both the questionnaire and iPad survey aimed 
to elicit surgical decision-making data regarding types of repair materials used, such 
as synthetic or biological meshes and the characteristics of these that determine sur-
geon choices. Important additional factors, including co-morbidities, safety, contami-
nation, and risk of recurrence, were included in the questionnaire, as well as the likely 
length of hospital stay. Use of the Ventral Hernia Working Group guidelines was also 
questioned. The second stage of this process will collect retrospective resource use 
data from patient records to determine patterns of care and cost that could improve 
surgical decision-making and patient outcomes. Results: To date, 16 paper-based 
questionnaires and 5 iPad surveys have been completed. Surgeons from the UK (7), 
Belgium (3), Germany (3) the Netherlands (2) and Italy (1) completed the paper-based 
questionnaire. ConClusions: There is sufficient agreement amongst surgeons to 
produce a patient management pathway, and additional results from ongoing data 
collection will improve confidence in the consensus.
ReseaRch On MethOds – Patient-Reported Outcomes studies
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objeCtives: Chronic urticaria (CU) (or chronic hives) can be inducible or sponta-
neous (also known as idiopathic urticaria) (CSU/CIU). Data supporting the impact 
of CSU/CIU on patients and comparison with other dermatological diseases are 
scarce. This study evaluated humanistic burden associated with CU relative to pso-
riasis (PsO) and different severity of PsO among the adults in 5 European (France, 
Germany, Italy, Spain and UK) countries. Methods: Data come from diagnosed 
CU (proxy for CSU) and PsO patients collected in the National Health and Wellness 
Survey (NHWS). Humanistic burden was measured through the mental and physi-
cal component score (MCS, PCS) of the SF-36v2 and SF-6D health utility score. 
Self-reported anxiety, depression and sleep difficulty were also assessed. NHWS 
collects data on PsO severity but not on CU severity. Multiple linear or logistic 
regressions was used to compare outcomes between patients with CU vs. overall 
PsO (included all severity levels) and CU vs. moderate-severe-PsO, controlling for 
patient characteristics. Results: Study included 769 CU patients and 7,857 PsO 
patients (26.9% moderate-severe). CU patients had lower (worse) MCS (mean±SE, 
42.2±0.39 vs. 44.6±0.16), PCS (45.2±0.34 vs. 46.8±0.14) and SF-6D score (0.65±0.005 
vs. 0.68±0.002) than overall PsO (all p< 0.001). Scores for moderate-severe-PsO 
were 43.2±0.25 (p< 0.05), 45.7±0.22 (p= NS) and 0.667±0.003 (p< 0.05) respectively. 
CU patients had higher adjusted odds of anxiety, depression and sleep difficulties 
than overall PsO [odds ratio (OR):1.63, 1.34 and 1.56, respectively, all p< 0.01]. There 
was no significant difference between moderate-severe-PsO (OR: 1.45, 1.12, and 
1.36, respectively) and CU patients for the same parameters. ConClusions: CU 
and PsO have a negative impact on patients’ quality of life. CU patients report 
significantly higher impairment and more psychological complaints than overall 
PsO patients. When compared to moderate-severe-PsO, patients with CU still have 
a significantly slightly higher impairment in mental status and lower utility and 
similar physical impairment and psychological complaints.
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objeCtives: The Self-Assessment of Treatment Version II (SAT-II) instrument has 
three versions: baseline; follow-up (FU); and last-visit versions. Baseline version 
measures pain level (one item) and impact of pain (six items). Follow-up and last-
visit versions measure improvement in the impact or level of pain due to treat-
ment. Last-visit also includes two items about treatment preferences. This study 
explored scoring of the SAT-II (baseline and last-visit). Scores were also assessed 
for their responsiveness to change. Methods: Data from 369 patients (42% female; 
mean age= 63) with painful diabetic peripheral neuropathy from a randomised, 
double-blind placebo-controlled trial (STEP) were used to test baseline and last-visit 
versions. Item-to-item spearman correlations and spearman correlations between 
summary scores and Brief Pain Inventory-Diabetic Neuropathy pain severity score 
(PSS) were tested. Factor analysis was conducted on the six impact items to develop 
a scoring algorithm (baseline or last-visit summary score). Analysis of variance 
measured responsiveness to treatment responder status as defined by PSS (both 
≥ 30% & ≥ 50% reduction from baseline) and Patient Global Impression of Change 
(PGIC; much/very much improved). Results: A single-factor structure for the six 
impact items was demonstrated for baseline and last-visit. Item-to-item correla-
tions (baseline: correlation (r)= 0.33 to 0.75; last-visit: r= 0.52 to 0.89) and correla-
tions between a sum of the impact items and PSS were significant for baseline 
(r= 0.39, p= 0.001) and last-visit (r= -0.46, p= 0.0001). A mean summary score of the 
impact items discriminated (all p< 0.0001) between non-responders and respond-
ers, respectively for each definition as follows: ≥ 30%, 0.6 (SD 0.9) vs 1.9(1.3); ≥ 50%, 
0.8 (1.0) vs. 2.3 (1.3); and PGIC, 0.6 (0.7) vs. 2.3 (1.2). ConClusions: The six impact 
items of the SAT-II can be scored as a summary measure on both the baseline and 
copula families available and conditional version of the Sklar’s theorem provides 
theoretical background of using covariates for copula parameters. The models 
were fitted by optimizing the pseudo maximum likelihood numerically using 
the R statistical software. Results: The associations between several biomarker 
couples were measured by correlation. Pearson’s (ρ ) and Kendall’s (τ ) correla-
tions were ρ = 0.55 and τ = 0.4 for VAS-HAQ and ρ = 0.66 and τ = 0.48 for VAS-DAS28. 
Additionally, the bivariate/trivariate dependences were modelled with or without 
assuming further covariates as e.g. age at first RA diagnosis or the type of therapy 
etc. ConClusions: The association among biomarkers is strongly positive, how-
ever the association within different subgroups of the RA patients can be signifi-
cantly different too. These differences should be taken into account in any further 
statistical analysis as not only the marginal distributions of biomarkers but their 
dependence structure can be instrumental in modelling too.
PRM133
OPeRatiOnal validatiOn Of health ecOnOMic decisiOn analytic 
MOdels
Corro Ramos I1, Al MJ2, Vemer P3, Feenstra TF4, van Voorn G5
1Institute for Medical Technology Assessment, Rotterdam, The Netherlands, 2Erasmus University, 
Rotterdam, The Netherlands, 3Unit HTA, Dept of Epidemiology University Medical Center 
Groningen (UMCG), Groningen, The Netherlands, 4University Medical Center Groningen, 
Groningen, The Netherlands, 5Biometris, Wageningen University and Research Center, 
Wageningen, The Netherlands
objeCtives: To validate health economic (HE) models by means of statistical 
comparison of model outcomes against empirical observations. Such a compari-
son is structured and the applicability of several existing validation techniques 
is discussed, with a special focus on statistical testing. When standard methods 
(95%-confidence intervals) are used several problems, both of a technical and philo-
sophical nature, are encountered. These problems are discussed. A new statisti-
cal approach is consequently proposed. Methods: The proposed method can be 
applied to validate HE models when the uncertainty around the input parameters 
of the model is assessed via probabilistic sensitivity analysis (PSA). It is based on 
the idea of establishing a level of accuracy in advance for the empirical observa-
tions and model outcomes should meet. If the model result falls within the limits 
determined by the pre-required accuracy, then the model result is considered valid. 
The number of valid results obtained in a PSA defines a measure of the reliability 
of the model. Embodying the method in a Bayesian framework allows defining 
such a reliability measure with statistical properties. Results: Existing approaches 
suffer from technical and interpretational problems. In addition, these methods 
are lacking a measure of overall reliability. Our new method (1) departs from clas-
sical statistical techniques, circumventing the noted problems, (2) can be used for 
both cohort and patient-level models and (3) makes use of all PSA outcomes. The 
method is demonstrated with the help of a case study in a published diabetes model 
(MICADO). ConClusions: Standard statistical techniques have to be applied very 
carefully on the comparison of model outcomes to empirical observations. They 
suffer from several problems. A new promising Bayesian approach is proposed that 
solves some of these issues. Our new method allows stepwise validation of the 
model as new data becomes available, which may increase the model’s validation 
status.
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objeCtives: Pharmaceuticals are usually granted a marketing authorisation on 
the basis of randomised controlled trials (RCTs). Occasionally the efficacy of a 
treatment is assessed without a randomised comparator group (either active or 
placebo). Our objective was to identify and develop a taxonomic account of eco-
nomic modelling approaches for pharmaceuticals approved without randomised 
control data. Methods: We searched PubMed, ISPOR Scientific Presentations 
and the website of UK health technology assessment (HTA) bodies for assess-
ments of the 75 indications granted a marketing authorisation by the FDA or 
EMA from Jan-1999 to May-2014 without RCT data. The outcome of interest was 
the approach to modelling efficacy data. Results: Fifty-one unique models 
were identified based on 29 peer-reviewed articles, 15 ISPOR abstracts, and 30 
health technology appraisals (HTAs). The majority of models (43/51) were based 
on ‘historical controls’ – comparisons to previous meta-analysis or pooling of tri-
als (5), individual trials (19), registries/case series (14), or expert opinion (7). The 
majority of drugs granted a marketing authorisation without a RCT had not been 
evaluated in a published economic model (45/75), with a low rate of submission 
to UK HTA agencies (28/98). ConClusions: There is considerable variation in 
the quality of models constructed for drugs granted a marketing authorisation 
without a RCT. The most common approach is of a naïve comparisons to historical 
data (using other trials/registry data as a control group), with considerable scope 
for bias.
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objeCtives: Complex abdominal wall reconstruction has been a challenging issue 
for surgeons for many years, with many factors affecting surgical decision-making 
and patient outcomes. In particular, complex procedures for ventral hernia repair 
represent a huge healthcare burden, particularly if two-step rather than one-step 
reconstruction is used. Effective abdominal wall reinforcement is among the goals of 
patient management. At present, there appears to be no consistent pathway for the 
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models. ConClusions: The specified mapping algorithms from the BDI index to 
the EQ-5D-3L index for patients with depressive disorders are acceptable for usage 
as approximation in cost-utility analyses. A further validation in independent sam-
ples is necessary to obtain more confidence in their performance.
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objeCtives: LPLD is an ultra-orphan genetic lipid disorder (prevalence 1-2/mil-
lion). It is associated with severe hypertriglyceridemia and an increased risk of 
acute pancreatitis. Other manifestations include eruptive xanthoma, fatigue, dif-
ficulty with concentrating and cardiopulmonary symptoms. Associated symptoms, 
complications and the fat-restricted diet affect Quality of Life (QOL). Currently no 
disease-specific measure exists to assess QOL and the burden of LPLD. As part of 
post approval commitments of alipogene tiparvovec, regulatory bodies requested 
the development of a reliable measure of QOL in LPLD. This study evaluates exist-
ing EORTC questionnaires QLQ-C30 and QLQ-PAN26, and a new questionnaire of 
disease burden devised by clinicians with experience in treating LPLD. Methods: 
To date, eight genetically confirmed LPLD-patients from four countries assessed 
the relevance and importance of each item of the three questionnaires. Patients’ 
ratings were discussed during an in-depth, face-to-face interview and the dis-
ease burden questionnaire was comprehensively discussed, analyzed and then 
modified where necessary. Results: Quantitative assessment showed that 25 
(45%) of the QLQ-C30 and QLQ-PAN26 questions were relevant to the majority of 
patients. The most relevant items were pain (6), fatigue and sleeping problems 
(4), digestive and dietary factors (4), work, daily and social activity restrictions (4) 
and impact on emotional functioning (3). Qualitative and quantitative analysis 
of the new questionnaire highlighted the unpredictability of pancreatitis attacks 
and the impact of the strict low fat diet on social and emotional factors. Less 
common clinical manifestations of LPLD (xanthoma, dyspnea) were very impor-
tant to those affected. The new questionnaire has been modified and items on 
alcohol use and painkillers added for ongoing evaluation. ConClusions: Five 
QOL domains relevant to LPLD have been identified using existing questionnaires. 
A new disease-specific questionnaire identifies significant impacts on patients’ 
lives. These instruments may help clinicians to effectively use pharmacological 
and genetic therapy to manage LPLD patients.
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objeCtives: The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is 
one of the most widely used health-related quality of life (HRQoL) specific ques-
tionnaires for patients with heart failure (HF). It provides two dimensions (physical 
and emotional) and a global score. However, there are some concerns about its 
factor structure, and different alternatives have been proposed, including even a 
third factor representing a social dimension. The objective of the present study 
was to study the internal structure of the MLHFQ, the unidimensionality of the 
total score, and to compare the different factor structures raised. Methods: We 
included 2565 patients hospitalized for HF, who were provided with the MLHFQ 
during hospitalization. The structural validity of the questionnaire was studied 
by confirmatory factor analysis (CFA) for categorical data, and the Rasch rating 
scale model. These two approaches were also applied to the different structures 
proposed. Results: The results of the CFA for the hypothesized model of two 
latent factors and the Rasch analysis confirmed the adequacy of the physical and 
emotional dimensions. We only found two problematic items within the total 
score. The results of the CFA applied to other two-factor structures proposed were 
not better than the results of the original structure. The Rasch analysis applied 
to the different social factors showed the best results for Munyombwe’s social 
dimension. ConClusions: The results support the validity of using the MLHFQ 
physical and emotional subscales in patients with HF, as well as the total score. 
In addition, the results confirmed the existence of a third social factor, and we 
recommend the use of Munyombwe’s social factor.
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last-visit versions, whilst other items should be scored individually. The last-visit 
version discriminates treatment response.
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objeCtives: In recent years, the healthcare industry has witnessed a trend for regula-
tory approvals of innovative technologies in oncology without head-to-head clinical 
trial evidence or Health Related Quality-of-Life (HRQoL) data. This yields a challenge 
to decision-makers who require a cost-effectiveness analysis (CEA) to conduct Health 
Technology Assessments. To demonstrate methodological approaches and potential 
data sources to address these gaps, we present a case study using recently approved 
drugs lenvatinib and sorafenib for management of radioiodine-refractory differenti-
ated thyroid cancer (RR-DTC). Methods: A vignette study was conducted to elicit 
utilities for RR-DTC health-states and estimate the impact of toxicities on HRQoL. 
Phase III clinical trial data with crossover correction were used to compare clinical-
endpoints of Progression Free Survival (PFS) and Overall Survival (OS) for both len-
vatinib and sorafenib. Adjustments for study population differences were addressed 
using Matching-Adjusted Indirect Comparison. PFS and OS data were extrapolated 
to 10 years using proportional hazard, accelerated time failure, individual parametric 
models and piecewise models and time in health states was estimated from the 
partitioning of survival time into pre- and post-progression. Results: Adjusted 
HRs for lenvatinib vs. sorafenib were estimated as 0.37(95%CI: 0.25-0.55) for PFS and 
0.79(0.45-1.37) for OS. PFS (stable) health-state utilities for each drug were adjusted 
using tumor response rates and incremental utility gain. Combining phase III toxicity 
rates with utility decrements yielded a total disutility of 0.042 for lenvatinib vs. 0.117 
for sorafenib. Survival extrapolation (undiscounted) provided estimates of incremen-
tal 0.66 LYS and 0.60 QALY for lenvatinib vs. sorafenib. ConClusions: This analysis 
demonstrated that in absence of head-to-head trials and QoL trial data, vignette utility 
studies and ITC may be used to aid with QALY analysis, especially in orphan diseases 
where limited data are available. Vignette studies and ITC can increase reliability of 
comparative-effectiveness data and support payers’ decision making.
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objeCtives: Lack of rigour in PRO data analysis leads to uncertainty around the 
quality of results impacting the extent to which conclusions can be drawn from 
the data. This study sought to provide guidelines for PRO efficacy data analysis for 
study sponsors in order to ensure confidence in PRO results by stakeholder decision 
makers. Methods: A targeted review was undertaken of guidelines for clinical 
trial and PRO data analysis, and published PRO analysis studies that demonstrated 
good practice in PRO efficacy analysis. The evidence was synthesised by a team 
comprising statistical and PRO experts experienced in the analysis of PRO efficacy 
data. An 8-step guideline was developed based on the available evidence. Results: 
Eight steps that will ensure high quality analysis of PRO trial efficacy data are (1) 
avoid unplanned or post analysis by developing a PRO specific SAP prior to data 
base lock, or document comprehensive PRO data analysis in the clinical trial SAP 
(2) ensure awareness of differing requirements across stakeholders in PRO data 
analysis/interpretation and adequately address this in the SAP to ensure (3) specify 
primary and secondary PRO endpoints and/or approaches to correcting for multi-
plicity (4) develop and specify appropriate approaches to handling missing data 
including sensitivity analysis (5) include analysis of PRO score change from base-
line (6) specify approaches to interpreting change from baseline data including 
any benchmarks which will be applied during interpretation (7) implement a 100% 
double programming approach alongside table review by statistically qualified team 
members (8) interpret PRO results not only in isolation but alongside other clini-
cal outcomes ConClusions: For PRO data to effectively inform decision making 
across all stakeholders, high standards of data analysis needs to be mandatory. This 
8-step guideline, if adhered to, will raise the standard of PRO data analysis reducing 
the likelihood that PRO data is discounted by decision makers.
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objeCtives: For cost-utility analyses, data on health state utilities, as provided by 
the EQ-5D-3L, is needed but not always available. This study specifies a mapping 
algorithm from the Beck Depression Inventory (BDI) index to the EQ-5D-3L index 
adjusted for specific socio-demographic variables for patients with depressive dis-
orders. Methods: A sample of 1,074 consecutive patients with depressive disorders 
from a psychotherapeutic outpatient clinic was included in the study. Standardized 
clinical interviews were applied to establish reliable diagnoses. For the prediction 
of the EQ-5D-3L index from the BDI index and selected patient socio-demographic 
characteristics, ordinary least squares regression with robust standard errors was 
used. Model prediction properties were tested using the root mean squared error 
and repeated random sub-sampling cross-validation. Results: The BDI index 
predicted the EQ-5D-3L index with a significant proportion of variance explained. 
The highest model goodness of fit was estimated for models with the BDI index 
and age as independent variables. The root mean squared error of the predicted 
EQ-5D-3L index in the validation samples ranged from 0.225 to 0.228 between the 
